June 11-17
<I>TheStreet.com</I> corrects its mistakes.
A June 8 story,
Dueling Drugs May End Up With Dual Approval, misspelled the name of a
Genzyme
(GENZ:Nasdaq) drug. It is Fabrazyme, not Fabryzyme. (
corrected June 11
)
A table in a June 8 story,
False Hopes for Sky High Growth Linger in Tech Valuations, incorrectly listed
Xilinx's
(XLNX:Nasdaq) trailing price-to-earnings ratio as 4.5. It is 42.5. The story also incorrectly stated that
Cisco's
(CSCO:Nasdaq) shares had fallen 84% since last March. They have actually fallen 75%. (
corrected June 11
)
Loading ...